Research programme: cancer therapeutics - Isogenica/NanoCarrier
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator CTT Cancer Targeting Technologies; NanoCarrier
- Developer Isogenica; NanoCarrier
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Finland
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Japan
- 06 May 2008 Karyon-CTT has been acquired and merged into Isogenica